Thorsten H Ecke

List of Publications by Year
in descending order

79	1,206	394421	414414
papers	citations	19 h-index	32 g-index

82	82	82	1917
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers. Clinical Chemistry, 2010, 56, e1-e48.	3.2	184
2	Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatinâ€based chemotherapy. Cancer, 2013, 119, 3012-3019.	4.1	82
3	TP53 gene mutations in prostate cancer progression. Anticancer Research, 2010, 30, 1579-86.	1.1	54
4	KISS1 Methylation and Expression as Tumor Stratification Biomarkers and Clinical Outcome Prognosticators for Bladder Cancer Patients. American Journal of Pathology, 2011, 179, 540-546.	3.8	44
5	Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study. Frontiers in Genetics, 2019, 10, 1237.	2.3	43
6	Complications and risk factors of transrectal ultrasound guided needle biopsies of the prostate evaluated by questionnaire. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 474-478.	1.6	40
7	Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability. World Journal of Urology, 2008, 26, 243-250.	2.2	39
8	Metastatic penile carcinoma â€“ an update on the current diagnosis and treatment options. Central European Journal of Urology, 2014, 67, 126-32.	0.3	35
9	miRâ€199aâ€3p and miRâ€214â€3p improve the overall survival prediction of muscleâ€invasive bladder cancer patients after radical cystectomy. Cancer Medicine, 2017, 6, 2252-2262.	2.8	31
10	EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer. Oncogene, 2020, 39, 6856-6870.	5.9	31
11	Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy. Anti-Cancer Drugs, 2013, 24, 422-425.	1.4	29
12	UBC^{Â®}Rapid Test for detection of carcinoma in situ for bladder cancer. Tumor Biology, 2017, 39, 101042831770162.	1.8	28
13	TP53 gene mutations as an independent marker for urinary bladder cancer progression. International Journal of Molecular Medicine, 2008, 21, 655-61.	4.0	28
14	Evaluation of Symptoms and Patients' Comfort for JJ-ureteral Stents With and Without Antireflux-membrane Valve. Urology, 2010, 75, 212-216.	1.0	26
15	Bladder Reconstruction with Human Amniotic Membrane in a Xenograft Rat Model: A Preclinical Study. International Journal of Medical Sciences, 2017, 14, 310-318.	2.5	24
16	Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation. BMC Cancer, 2020, 20, 230.	2.6	24
17	Evaluation of a New Survivin ELISA and UBCÂ® Rapid for the Detection of Bladder Cancer in Urine. International Journal of Molecular Sciences, 2018, 19, 226.	4.1	23
18	The Impact of Gender on Outcomes in Patients With Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer, 2013, 11, 346-352.	1.9	21

#	Article	IF	Citations
19	UBCÂ® Rapid Testâ€"A Urinary Point-of-Care (POC) Assay for Diagnosis of Bladder Cancer with a focus on Non-Muscle Invasive High-Grade Tumors: Results of a Multicenter-Study. International Journal of Molecular Sciences, 2018, 19, 3841.	4.1	21
20	Repair of a vesico-vaginal fistula with amniotic membrane â€" Step 1 of the IDEAL recommendations of surgical innovation. Central European Journal of Urology, 2015, 68, 459-61.	0.3	19
21	Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation. Anticancer Research, 2005, 25, 635-41.	1.1	19
22	Activating Telomerase TERT Promoter Mutations and Their Application for the Detection of Bladder Cancer. International Journal of Molecular Sciences, 2020, 21, 6034.	4.1	17
23	Preliminary Results of a Multicentre Study of the UBC Rapid Test for Detection of Urinary Bladder Cancer. Anticancer Research, 2015, 35, 2651-5.	1.1	17
24	Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer. Scientific Reports, 2017, 7, 12682.	3.3	16
25	Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 423-431.	1.6	16
26	Evaluation of Therapeutic Targets in Histological Subtypes of Bladder Cancer. International Journal of Molecular Sciences, 2021, 22, 11547.	4.1	16
27	Human amniotic membrane dressing for the treatment of an infected wound due to an entero-cutaneous fistula: Case report. International Journal of Surgery Case Reports, 2018, 51, 11-13.	0.6	15
28	Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 30.e15-30.e21.	1.6	14
29	Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Oncology Reports, 2006, 16, 1381-8.	2.6	14
30	Molecular identification of telomerase reverse transcriptase (TERT) promotor mutations in primary and recurrent tumors of invasive and noninvasive urothelial bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 77.e17-77.e25.	1.6	12
31	Nephrocutaneous Bypass in Ureteral Obstruction. Urology, 2010, 76, 480-485.	1.0	11
32	Vinflunine as second-line treatment in platin-resistant metastatic urothelial carcinoma. Anti-Cancer Drugs, 2011, 22, 9-17.	1.4	11
33	Presentation of a method at the Exploration Stage according to IDEAL: Percutaneous nephrolithotomy (PCNL) under local infiltrative anesthesia is a feasible and effective method - retrospective analysis of 439 patients. International Journal of Medical Sciences, 2017, 14, 302-309.	2.5	11
34	Prognostic model for overall survival in patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.. Journal of Clinical Oncology, 2012, 30, 4524-4524.	1.6	11
35	Targeted agents in second-line bladder cancer therapy. Anti-Cancer Drugs, 2012, 23, 1003-1015.	1.4	10
36	Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 48.e1-48.e8.	1.6	10

#	Article	IF	Citations
37	Application of Dried Human Amnion Graft to Improve Post-Prostatectomy Incontinence and Potency: A Randomized Exploration Study Protocol. Advances in Therapy, 2020, 37, 592-602.	2.9	10
38	Outcome prediction for prostate cancer detection rate with artificial neural network (ANN) in daily routine. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 139-144.	1.6	9
39	Relationship between 6â€•and 9â€•month progressionâ€free survival and overall survival in patients with metastatic urothelial cancer treated with firstâ€line cisplatinâ€based chemotherapy. Cancer, 2013, 119, 3020-3026.	4.1	9
40	External Validation of an Artificial Neural Network and Two Nomograms for Prostate Cancer Detection. ISRN Urology, 2012, 2012, 1-6.	1.5	8
41	Urinary thiosulfate as failed prostate cancer biomarker â€“ an exemplary multicenter re-evaluation study. Clinical Chemistry and Laboratory Medicine, 2015, 53, 477-83.	2.3	7
42	Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer. Advances in Experimental Medicine and Biology, 2015, 867, 293-316.	1.6	7
43	Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma1. Bladder Cancer, 2016, 2, 341-349.	0.4	7
44	Body mass index (BMI) and mutations of tumor suppressor gene p53 (TP53) in patients with urinary bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 470-473.	1.6	6
45	Successful evacuation of large perirenal hematoma after extracorporeal shock wave lithotripsy (ESWL) â€•step 1 of the IDEAL recommendations of surgical innovation. Clinical Case Reports (discontinued), 2017, 5, 123-125.	0.5	6
46	Retrospective analysis of a surgical innovation using the IDEAL framework: radical cystectomy with epidural anaesthesia. Journal of International Medical Research, 2017, 45, 714-722.	1.0	6
47	Diagnostic and Prognostic Potential of MicroRNA Maturation Regulators Drosha, AGO1 and AGO2 in Urothelial Carcinomas of the Bladder. International Journal of Molecular Sciences, 2018, 19, 1622.	4.1	6
48	Nomograms including the UBC^{Â®} Rapid test to detect primary bladder cancer based on a multicentre dataset. BJU International, 2022, 130, 754-763.	2.5	6
49	TP53 gene mutations as an independent marker for urinary bladder cancer progression. International Journal of Molecular Medicine, 0, , .	4.0	5
50	Human Amniotic Membrane Is Not Suitable for the Grafting of Colon Lesions and Prevention of Adhesions in a Xenograft Rat Model. Surgical Innovation, 2017, 24, 313-320.	0.9	5
51	Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy.. Journal of Clinical Oncology, 2013, 31, 256-256.	1.6	5
52	Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene Assessment. International Journal of Molecular Sciences, 2022, 23, 7898.	4.1	5
53	Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer. International Journal of Molecular Sciences, 2016, 17, 1879.	4.1	4
54	Prognostic and discriminative power of the 7th TNM classification for patients with surgically treated papillary renal cell carcinoma: results of a multi-institutional validation study (CORONA) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 57	1.0	4

#	Article	IF	Citations
55	Establishment and Characterization of an Empirical Biomarker SS/PV-ROC Plot Using Results of the UBCÂ® Rapid Test in Bladder Cancer. Entropy, 2020, 22, 729.	2.2	4
56	Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Oncology Reports, 0, , .	2.6	4
57	Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer. Anticancer Research, 2003, 23, 957-62.	1.1	4
58	Evaluating the Use of Prostate-Specific Antigen as an Instrument for Early Detection of Prostate Cancer beyond Urologists: Results of a Representative Cross-Sectional Questionnaire Study of General Practitioners and Internal Specialists. Urologia Internationalis, 2014, 93, 160-169.	1.3	3
59	Protocol for a Randomized Phase II Trial for Mesh Optimization by Autologous Plasma Coating in Prolapse Repair: IDEAL Stage 3. Advances in Therapy, 2017, 34, 995-1006.	2.9	3
60	Registry of implants for the reconstruction of pelvic floor in males and females: A feasibility case series. International Journal of Surgery, 2017, 42, 27-33.	2.7	3
61	Transvesical Suprapubic Externalization of Ureteral Stents - Introduction of a Surgical Innovation at the Development Stage. Urologia Internationalis, 2017, 99, 69-76.	1.3	3
62	Quality of life and pain relief in men with metastatic castrationâ€resistant prostate cancer on cabazitaxel: the nonâ€interventional â€˜QoLiTimeâ€™ study. BJU International, 2017, 119, 731-740.	2.5	3
63	SWI/SNF Alterations in Squamous Bladder Cancers. Genes, 2020, 11, 1368.	2.4	3
64	Illumination of a Vision 2020â€"Urinary Based Biomarkers for Bladder Cancer on the Way to Clinical Decisionsâ€"Dream or Nightmare?. International Journal of Molecular Sciences, 2020, 21, 1694.	4.1	3
65	DISCOVERY OF THE METHYLATION OF THE METASTASIS SUPPRESSOR GENE, KISS-1, IN BLADDER CANCER. Journal of Urology, 2009, 181, 374-374.	0.4	2
66	Illumination of a Visionâ€"How Arthur Rimbaud Will Give Us Motivation to Find New Input into Bladder Cancer Biomarker Research. International Journal of Molecular Sciences, 2017, 18, 2463.	4.1	2
67	Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of KRT5, KRT20, and ERBB2 in Muscle-Invasive Bladder Cancer Treated by Adjuvant Chemotherapy. International Journal of Molecular Sciences, 2020, 21, 7420.	4.1	2
68	Identifying the Molecular Mechanisms Contributing to Progression, Metastasis, and Death in Low-grade Nonâ€"muscle-invasive Bladder Cancer: A Case Report. European Urology Open Science, 2021, 27, 29-32.	0.4	2
69	Clinical and pathological features of metastatic adenocarcinoma of the prostate to the ileum. Central European Journal of Urology, 2014, 67, 357-60.	0.3	1
70	Health-related quality of life and rates of toxicity after high-dose-rate brachytherapy in combination with external beam radiation therapy for high-risk prostate cancer. Investigative and Clinical Urology, 2020, 61, 250.	2.0	1
71	Exploring solid-phase proximity ligation assay for survivin detection in urine. PLoS ONE, 2022, 17, e0270535.	2.5	1
72	Tumormarker beim Blasentumor: Aussichten fÃ¼r den klinischen Alltag / Tumor markers for bladder cancer: outlook for routine use. Laboratoriums Medizin, 2010, 34, 77-86.	0.6	0

#	Article	IF	Citations
73	Evidence in Urologic- and Pelvic-Surgery Research: Finding the IDEAL Way of Reporting. BioMed Research International, 2017, 2017, 1-2.	1.9	0
74	Evaluating the Utility of Combined Bladder Cancer Biomarkers, the Molecular Prognostication of Tumor Subtypes, or What Else Is Needed to Illuminate Our Vision?. International Journal of Molecular Sciences, 2020, 21, 9657.	4.1	0
75	We need to know the treatment urethral injuries. Central European Journal of Urology, 2013, 66, 359-60.	0.3	0
76	Progression-free survival as an endpoint for clinical trials in first-line metastatic urothelial cancer.. Journal of Clinical Oncology, 2013, 31, 251-251.	1.6	0
77	Cisplatin-based combination chemotherapy in elderly patients with metastatic urothelial cancer.. Journal of Clinical Oncology, 2013, 31, 269-269.	1.6	0
78	Impact of obesity in patients with metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2015, 33, 346-346.	1.6	0
79	Molecular Diagnostic and Prognostication Assays for the Subtyping of Urinary Bladder Cancer Are on the Way to Illuminating Our Vision. International Journal of Molecular Sciences, 2022, 23, 5620.	4.1	0